FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2805951217> ?p ?o ?g. }

• W2805951217 endingPage "43" @default.
• W2805951217 startingPage "29" @default.
• W2805951217 abstract "Clinical Insights: Neoadjuvant Therapy in Breast Cancer Recommendation and predictors of pathologic responseVladimir F Semiglazov & Vladislav V SemiglazovVladimir F SemiglazovVladimir F Semiglazov is a professor, doctor of medical sciences, corresponding member of the Russian Academy of Medical Sciences, and an academician of the Russian Academy of Natural Sciences. The main spheres of his scientific research are the study pathogenesis of tumors, organization of clinical trials, and accomplishment of the methods of the surgical treatment of cancer, neoadjuvant and adjuvant systemic treatment of breast cancer, and treatment of metastatic breast cancer. He is the author of more than 340 publications, including seven monographs.Search for more papers by this author & Vladislav V SemiglazovVladislav V Semiglazov is a doctor of medical sciences and Chief of the Oncology Department of First Pavlov State Medical University of St Petersburg (Russia). His research interest is early diagnostics and treatment of breast cancer. The majority of his scientific works are devoted to ductal carcinoma in situ management.Search for more papers by this authorPublished Online:21 Feb 2014https://doi.org/10.2217/ebo.13.498AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: Summary Three main goals for neoadjuvant systemic therapy in breast cancer were defined: to reduce mortality from breast cancer, to improve surgical options, and to acquire early information on response and biology of the disease. Advances in knowledge of breast cancer biology heterogeneity has led to the use of different types of neoadjuvant systemic therapy: neoadjuvant chemotherapy, neoadjuvant endocrine therapy and neoadjuvant target therapy (in HER2-positive breast cancer). References1 Mathew J , Asgeirsson K , Cheung K , Chan S , Dahda A , Robertson J . Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions . Eur. J. Surg. Oncol. 35 (2) , 113 – 122 (2009) . Crossref, Medline, CAS, Google Scholar2 Untch M , Fasching P , Konechny G , von Koch F , Conrad U . PREPARE trial: a randomized Phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoltin alfa in primary breast cancer – results at the time of surgery . Ann. Oncol. 22 , 1988 – 1998 (2011) . Crossref, Medline, CAS, Google Scholar3 Cebrecos I , Cordoba O , Deu J , Xercavins J , Rubio I . Can we predict local recurrence in breast conservative surgery after neoadjuvant chemotherapy? Eur. J. Surg. Oncol. 36 , 528 – 534 (2010) . Crossref, Medline, CAS, Google Scholar4 Monrigal E , Dauplat J , Gimbergues P , Bouedec G , Reyronie M . Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study . Eur. J. Surg. Oncol. 37 , 864 – 870 (2011) . Crossref, Medline, CAS, Google Scholar5 Colleoni M , Viale G , Zahrieh D . Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment . Clin. Cancer Res. 10 , 6622 – 6628 (2004) . Crossref, Medline, CAS, Google Scholar6 Gianni L , Baselga J , Eiermann W , Porta J , Semiglazov V . Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, metotrexate and fluorouracil as adjuvant or primary systemic therapy: European cooperative trial in operable breast cancer . J. Clin. Oncol. 27 (15) , 2474 – 2481 (2009) . Crossref, Medline, CAS, Google Scholar7 Bear HD , Anderson S , Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27 . J. Clin. Oncol. 24 (13) , 2019 – 2027 (2006) . Crossref, Medline, CAS, Google Scholar8 Von Minckwitz G , Untch M , Blohmer JU , Costa S , Eidtmann H . Defition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes . J. Clin. Oncol. 30 , 1796 – 1804 (2012) . Crossref, Medline, Google Scholar9 Schott A , Hayes D . Defining the benefits of neoadjuvant chemotherapy for breast cancer . J. Clin. Oncol. 30 , 1747 – 1749 (2012) . Crossref, Medline, Google Scholar10 Eiermann W , Paepke S , Appfelstaedt J . Preoperative treatment of postmenopausal patients with letrozole: a randomized double-blind multicenter study . Ann. Oncol. 12 , 1527 – 1532 (2001) . Crossref, Medline, CAS, Google Scholar11 Smith I , Heys S , Hutcheon A . Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel . J. Clin. Oncol. 20 , 1456 – 1466 (2002) . Crossref, Medline, CAS, Google Scholar12 Smith I . Anstrozole versus tamoxifen as preoperative therapy for oestrogen receptor positive breast cancer in postmenopausal women: combined analysis of the IMPACT and PROACT trials. Presented at: the 4th European Breast cancer Conference, Hamburg, Germany, 16–20 March 2004 . Google Scholar13 Smith I , Dowsett M , Ebbs S . Neoadjuvant treatment of postmenopausal breast cancer with anastrazole, tamoxifen, or both in combination: The immediate preoperative anastrazole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trual . J. Clin. Oncol. 23 (22) , 5018 – 5116 (2005) . Google Scholar14 Cataliotti L , Buzdar A , Noguchi S . Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to tamoxifen (PROACT) . Trial Cancer 106 (10) , 2095 – 2103 (2006) . Crossref, CAS, Google Scholar15 Semiglazov V , Semiglazov V , Dashyan G , Ziltsova E , Ivanov V . Phase II randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positiv breast cancer . Cancer 110 , 244 – 254 (2007) . Crossref, Medline, CAS, Google Scholar16 Semiglazov VF , Semiglazov VV . Neoadjuvant systemic therapy in breast cancer. In: Neoadjuvant Chemotherapy: Current Applications in Clinical Practice. Bathe OF (Ed.). InTech, Rijeka, Croatia , 1 – 22 (2012) . Google Scholar17 Goldhirsch A , Ingle J , Gelber R , Coates A , Thürlimann B , Senn H . Thresholds for therapies: highlights of the St. Gallen International Expert consensus on the primary therapy of early breast cancer . Ann. Oncol. 20 (4) , 1133 – 1144 (2009) . Google Scholar18 Gianni L , Eiermann W , Semiglazov V , Manikhas A , Lluch A . Neoadjuvant chemotherapy with trastuzumab, followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER-positive, locally advanced breast cancer (the NOAH trial): a randomized controlled superiority 1 trial with a parallel HER2-negative cohort . Lancet 375 , 377 – 384 (2010) . Crossref, Medline, CAS, Google Scholar19 Baselga J , Carbonell X , Castaneda-Soto N . Phase II study of efficacy, safety, and pharmacokinetics of trastuzumabmonotherapy administered on a 3-weekly schedule . J. Clin. Oncol. 23 , 2162 – 2171 (2005) . Crossref, Medline, CAS, Google Scholar20 Slamon D , Leyland-Jones B , Shak S . Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that over expresses HER2 . N. Engl. J. Med. 344 , 783 – 792 (2001) . Crossref, Medline, CAS, Google Scholar21 Marty M , Cognetti F , Maraninchi D . Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group . J. Clin. Oncol. 23 , 4265 – 4274 (2005) . Crossref, Medline, CAS, Google Scholar22 Romond E , Perez E , Bryant J . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N. Engl. J. Med. 353 , 1673 – 1684 (2005) . Crossref, Medline, CAS, Google Scholar23 Slamon D , Eiermann W . Phase III randomized trial comparing doxorubicin and cyclophophomide followed by docetoxel (FC-T) with doxorubicin and cyclophophomide followed by docetaxel and trastuzumab (AC-TH) with docetoxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study . Breast Cancer Res. Treat. 94 (Suppl. 1) , S5 (2005) . Google Scholar24 Semiglazov V , Eiermann W , Zambetti M , Manikhas A , Bozhok A . Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the neoadjuvant herceptin (NOAH) study . Eur. J. Surg. Oncol. 37 , 856 – 863 (2011) . Crossref, Medline, CAS, Google Scholar25 Gianni L , Pienkowski T , Roman L , Tseng L , Liu M . Addition of pertuzumab(p) to trastuzumab (H)-based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: result of a randomized Phase II study (NEOSPHERE) . Breast 20 (Suppl.) , 573 (2011) . Google Scholar26 Baselga J , Bradbury I , Eidtmann H et al. NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, Phase 3 trial . Lancet 379 (9816) , 633 – 640 (2012) . Crossref, Medline, CAS, Google Scholar27 Blackwell KL , Burstein HJ , Storniolo AM . Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab refractory metastatic breast cancer . J. Clin. Oncol. 28 , 1124 – 1130 (2010) . Crossref, Medline, CAS, Google Scholar28 Blackwell KL , Burstein HJ , Storniolo AM et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2- positive metastatic breast cancer: final results from the EGF104900 Study . J. Clin. Oncol. 30 , 2585 – 2592 (2013) . Crossref, Google Scholar29 Semiglazov V . How to handle breast cancer patients with complete response following neoadjuvant chemotherapy . Eur. J. Surg. Oncol. 34 (9) , 1025 (2008) . Google Scholar30 Clouth B , Chandrasekharan S , Inwang R , Smith S , Davidson N , Sauven P . The surgical managlment of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer . Eur. J. Surg. Oncol. 33 , 961 – 966 (2007) . Crossref, Medline, CAS, Google Scholar31 Ring A , Smith I , Ashley S . Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotharapy for early breast cancer . Br. J. Cancer 91 , 2012 – 2017 (2004) . Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Clinical Insights: Neoadjuvant Therapy in Breast CancerMetrics Downloaded 18 times History Published online 21 February 2014 Published in print February 2014 Information© Future Medicine Ltd© Future Medicine LtdPDF download" @default.
• W2805951217 created "2018-06-13" @default.
• W2805951217 creator A5049342417 @default.
• W2805951217 creator A5068100907 @default.
• W2805951217 date "2014-02-01" @default.
• W2805951217 modified "2023-09-26" @default.
• W2805951217 title "Recommendation and predictors of pathologic response" @default.
• W2805951217 cites W1987326983 @default.
• W2805951217 cites W1994926267 @default.
• W2805951217 cites W1995692008 @default.
• W2805951217 cites W2008004993 @default.
• W2805951217 cites W2052123853 @default.
• W2805951217 cites W2057084727 @default.
• W2805951217 cites W2058585724 @default.
• W2805951217 cites W2100375606 @default.
• W2805951217 cites W2101824720 @default.
• W2805951217 cites W2102773208 @default.
• W2805951217 cites W2104919541 @default.
• W2805951217 cites W2111578514 @default.
• W2805951217 cites W2124184879 @default.
• W2805951217 cites W2138734774 @default.
• W2805951217 cites W2146384083 @default.
• W2805951217 cites W2147415463 @default.
• W2805951217 cites W2149773268 @default.
• W2805951217 cites W2151859419 @default.
• W2805951217 cites W2153158488 @default.
• W2805951217 cites W2156556190 @default.
• W2805951217 cites W2157250162 @default.
• W2805951217 cites W2166335360 @default.
• W2805951217 cites W2170241131 @default.
• W2805951217 cites W2318605753 @default.
• W2805951217 doi "https://doi.org/10.2217/ebo.13.498" @default.
• W2805951217 hasPublicationYear "2014" @default.
• W2805951217 type Work @default.
• W2805951217 sameAs 2805951217 @default.
• W2805951217 citedByCount "0" @default.
• W2805951217 crossrefType "other" @default.
• W2805951217 hasAuthorship W2805951217A5049342417 @default.
• W2805951217 hasAuthorship W2805951217A5068100907 @default.
• W2805951217 hasConcept C15744967 @default.
• W2805951217 hasConcept C71924100 @default.
• W2805951217 hasConceptScore W2805951217C15744967 @default.
• W2805951217 hasConceptScore W2805951217C71924100 @default.
• W2805951217 hasLocation W28059512171 @default.
• W2805951217 hasOpenAccess W2805951217 @default.
• W2805951217 hasPrimaryLocation W28059512171 @default.
• W2805951217 hasRelatedWork W1506200166 @default.
• W2805951217 hasRelatedWork W1995515455 @default.
• W2805951217 hasRelatedWork W2039318446 @default.
• W2805951217 hasRelatedWork W2048182022 @default.
• W2805951217 hasRelatedWork W2080531066 @default.
• W2805951217 hasRelatedWork W2604872355 @default.
• W2805951217 hasRelatedWork W2748952813 @default.
• W2805951217 hasRelatedWork W2899084033 @default.
• W2805951217 hasRelatedWork W3032375762 @default.
• W2805951217 hasRelatedWork W3108674512 @default.
• W2805951217 isParatext "false" @default.
• W2805951217 isRetracted "false" @default.
• W2805951217 magId "2805951217" @default.
• W2805951217 workType "other" @default.